LENZ Therapeutics reported fourth quarter and full year 2025 financial results, with net product sales of $1.6 million from VIZZ commercial launch in October 2025, total revenue of $19.1 million including license fees, and net loss of $82.1 million for the year. Early commercial highlights include over 45,000 paid prescriptions on pace through Q1 2026 and sales force expansion.
Key takeaways
VIZZ launched October 2025; Q4 2025 net product sales $1.6 million from over 20,000 filled prescriptions
Over 6,500 unique prescribers in Q4 2025, on pace for over 10,000 through Q1 2026 with 55% writing multiple prescriptions
Cash, cash equivalents and marketable securities $292.3 million as of December 31, 2025
Full year 2025 net loss $82.1 million or $2.85 per share, compared to $49.8 million or $2.34 per share in 2024
License revenue $17.5 million in 2025 from ex-U.S. agreements including $7.5 million upfront and $10.0 million milestones
Expanding sales force from 88 to 117 territories, fully deployed in Q2 2026